Craig Rosen, MD
Interventional Cardiology · Morristown, NJNPI 1073512356
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $20,565 of the $26,147 with a category attached, or 78.7%. 36 manufacturers reported payments, led by Cardiovascular Systems Inc. at 34.2% of the total.
Across 659 payments — averaging $39.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$9K
- Abbott$7K
- Medtronic$5K
- Boston Scientific$700
- Spectrawave, Inc$600
- Novartis$431
- plus $4K from 30 others
What the payments were for
- Consulting fees$1,0004%
- Speaking & faculty fees$2,4809%
- Travel & lodging$2,0878%
- Food & beverage$20,56579%
- Entertainment$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 170 | $8,930 |
| Abbott | 181 | $7,250 |
| Medtronic(2 entities) | 108 | $4,681 |
| Boston Scientific | 17 | $700 |
| Spectrawave, Inc | 5 | $600 |
| Novartis | 42 | $431 |
| AstraZeneca | 17 | $373 |
| Philips North America LLC | 4 | $356 |
| Edwards Lifesciences | 2 | $336 |
| Amgen | 21 | $304 |
| Chiesi USA, Inc. | 15 | $219 |
| Opsens Inc. | 4 | $196 |
| Asahi Intecc USA, Inc. | 1 | $180 |
| Abiomed | 3 | $165 |
| Teleflex LLC | 2 | $161 |
| Pfizer | 11 | $151 |
| Irhythm Technologies, Inc. | 3 | $130 |
| Stryker | 2 | $124 |
| Johnson & Johnson | 8 | $108 |
| Cardiva Medical, Inc. | 5 | $106 |
| Merck | 5 | $83 |
| E.r. Squibb & Sons, L.L.C. | 6 | $82 |
| Novo Nordisk | 4 | $67 |
| Biosense Webster, Inc. | 2 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $63 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $53 |
| Penumbra, Inc. | 3 | $47 |
| Atricure, Inc. | 2 | $45 |
| Boehringer Ingelheim | 2 | $23 |
| Heartflow, Inc. | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Shockwave Medical, Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Diamondback Coronary$6,289
- RESOLUTE ONYX$1,628
- Coronary Orbital Atherectomy System$1,264
- DRAGONFLY OPSTAR$794
- Xience Sierra Coronary Stent System$548
- HyperVue Imaging System$480
- Starlight Imaging Catheter$480
- XIENCE SKYPOINT$479
- Optis Coronary Imaging System$432
- SYMPLICITY G3$421
- Resolute$278
- OPTIS$272
- (BQ9) Coronary IVUS$259
- ONYX FRONTIER$252
- Xience V coronary stent system$219
- Asahi Peripheral Vascular Wires$180
- KONECT RESILIA$171
- GUIDELINER$157
- CoreValve Evolut$144
- OptoWire$139
How this compares
$26,147 in reported general payments places this provider in the 75th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 451 | $605,639 |
| VyndaqelTafamidis Meglumine | 15 | $335,252 |
| XareltoRivaroxaban | 189 | $222,184 |
| Repatha SureclickEvolocumab | 164 | $160,195 |
| EntrestoSacubitril/Valsartan | 72 | $75,801 |
| MultaqDronedarone Hcl | 33 | $52,068 |
| Praluent PenAlirocumab | 38 | $47,179 |
| VascepaIcosapent Ethyl | 35 | $25,278 |
| Ezetimibe | 591 | $15,257 |
| EdarbiAzilsartan Medoxomil | 19 | $12,655 |
| Atorvastatin Calcium | 1,092 | $11,645 |
| Metoprolol Succinate | 737 | $11,618 |
| Valsartan | 272 | $11,327 |
| BrilintaTicagrelor | 16 | $10,673 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 146 | $10,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndaqel | $151 | $940,891466 claims |
| Johnson & JohnsonXarelto | $108 | $222,184189 claims |
| NovartisEntresto | $431 | $75,80172 claims |
| Sanofi-aventis U.S. LLCMultaq | $63 | $52,06833 claims |
| AstraZenecaBrilinta | $373 | $10,67316 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $14 | $10,43227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Morristown
- Dimitrios KarmpaliotisMorristown$129K
- Nazir SavjiMorristown$50K
- Amirali MasoumiMorristown$45K
- Mark BlumMorristown$41K
- John CosmiMorristown$15K
- David FreilichMorristown$15K
- Ankitkumar PatelGlen Ridge$408K
- Ziad AbbudOcean$360K
- Ramin HastingsHasbrouck Heights$295K
- Michael LimHackensack$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.